Key result
Targeting calcineurin directly may not be a viable therapeutic strategy for cardiac hypertrophy due to its dual adaptive and maladaptive roles, though its downstream pathways offer potential targets.
Design
Review
Authors
Loading...
Direct calcineurin inhibition warrants clinical caution in hypertrophy; leaves open downstream pathway targeting for future research.
Calcineurin itself may not be a viable direct drug target for heart failure due to its dual adaptive and maladaptive roles, but downstream transcriptional pathways may offer novel therapeutic targets.
Fiedler et al. (2005) conducted a review in Cardiac hypertrophy and heart failure. Calcineurin targeting was evaluated. Targeting calcineurin directly may not be a viable therapeutic strategy for cardiac hypertrophy due to its dual adaptive and maladaptive roles, though its downstream pathways offer potential targets.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: